BioAdaptives (BDPT) director granted Series D preferred shares as compensation

Rhea-AI Filing Summary

BioAdaptives, Inc. director reports stock-based board compensation. A company director received 2,286 shares of BioAdaptives Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share has a stated par value of $0.0001 and is convertible into 100 shares of common stock, for an underlying 228,600 common shares, subject to a 4.9% beneficial ownership limitation.

No Series D shares may be converted until six months after issuance, except that conversion occurs immediately upon liquidation. Each preferred share carries 100 votes in stockholder matters, and the conversion right does not expire. Following this transaction, the reporting person held 57,217 derivative securities in the form of Series D Convertible Preferred Stock, owned directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FRISSORA MARK P

Role Director

Type	Security	Shares	Price	Value
Other	Series D Convertible Preferred Stock	2,286	$0.00	--

Holdings After Transaction: Series D Convertible Preferred Stock — 57,217 shares (Direct)

Footnotes (1)

1. Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRISSORA MARK P

(Last) (First) (Middle)

C/O BIOADAPTIVES, INC.

2620 REGATTA DRIVE, SUITE 102

(Street)

LAS VEGAS NV 89128

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOADAPTIVES, INC. [ BDPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D Convertible Preferred Stock	(2)	01/01/2026		J(1)		2,286		07/01/2026	(2)	Common Stock	228,600	$0(1)	57,217	D

Explanation of Responses:

1. Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person.

2. The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.

Remarks:

	/s/ Mark P. Frissora	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioAdaptives (BDPT) disclose for its director?

A director received 2,286 shares of Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement.

How many BioAdaptives (BDPT) common shares are underlying the director’s preferred stock grant?

Each Series D Convertible Preferred share is convertible into 100 common shares, so 2,286 preferred shares represent 228,600 common shares, subject to a 4.9% beneficial ownership limit.

When can the BioAdaptives (BDPT) Series D preferred shares be converted into common stock?

The Series D Convertible Preferred Stock may not be converted until six months after the date of issuance, except that it converts immediately in a liquidation event.

What voting rights are attached to the BioAdaptives (BDPT) Series D Convertible Preferred Stock?

Each share of Series D Convertible Preferred Stock is entitled to 100 votes on matters of the issuer at stockholder meetings or consent solicitations, without regard to the beneficial ownership limitation.

What is the beneficial ownership limitation on the BioAdaptives (BDPT) Series D Convertible Preferred Stock?

Conversion of the Series D Convertible Preferred Stock is subject to a 4.9% beneficial ownership limitation, restricting how much common stock can be held through conversion.

How many Series D preferred shares does the BioAdaptives (BDPT) director hold after this transaction?

After the reported transaction, the director beneficially owned 57,217 derivative securities in the form of Series D Convertible Preferred Stock, held directly.